flanders.bio is an independent life sciences cluster organisation based in Flanders, Belgium

flanders.bio is a dynamic, member driven organisation with currently more than 350 members from Belgium and abroad. We help our members to create value by organising Networking and Training Activities, supporting Internationalisation, providing Services and building Expertise. flanders.bio and its members want to be the proud advocates of a reputable global-impact ecosystem in life sciences.

News from flanders.bio and its members

V-Bio Ventures leads Camel-IDS EUR 37m Series A financing to develop cancer targeted radiopharmaceuticals

Camel-IDS, a VUB spin-off company developing cancer-targeted radiopharmaceuticals, today secured EUR 37m in a Series A investment round led by V-Bio Ventures (Belgium) and Gimv (Belgium), joined by the co-lead investors HealthCap (Sweden), Novo Seeds (Denmark), Pontifax (Israel) and BioMedPartners (Switzerland). Existing investors also participated. The proceeds will enable Camel-IDS to run a phase Ib/II trial with its lead program CAM-H2 targeting HER2-positive brain metastatic breast cancer, while further progressing and broadening its preclinical pipeline.

Finance | 15 November 18 Read more

Mithra Announces the Completion of its Lead Clinical Phase III Programme for Estelle®

Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the completion of the Phase III Estelle® study in the US and Canada. Estelle® is Mithra’s novel combined oral contraceptive (COC), containing 15 mg Estetrol (E4)/ 3 mg drospirenone (DRSP). Top line data remain on track to be reported in Q1 2019.

ERS Genomics and Syngulon Sign License Agreement on CRISPR-Cas9 Genome Editing Patents for Industrial Applications

ERS Genomics Ltd and Syngulon, a synthetic biology startup developing original genetic technologies using bacteriocins, announced today a non-exclusive license agreement which provides Syngulon with worldwide access to ERS’ CRISPR-Cas9 genome editing intellectual property for use in combination with Syngulon Patent Rights. ERS Genomics holds rights to the foundational CRISPR-Cas9 patent portfolio from Dr. Emmanuelle Charpentier, an inventor of the breakthrough gene-editing technology.

Convert Pharmaceuticals appoints Mariola Söhngen as new CEO

Convert Pharmaceuticals, a Belgian biotech company developing anti-cancer therapeutics, announces that Dr Mariola Söhngen joined as CEO, as the company gears up for its first-in-human clinical trials with its lead program.

People | 08 November 18 Read more

flanders.bio events, trainings & international missions

Strategic Partners